EGFR+ NSCLC Combination Therapies Improve Outcomes but Increase Side Effects: Patient-Specific Factors Essential for Treatment Decisions

Combining therapies for EGFR-positive non-small cell lung cancer (NSCLC) simultaneously increases both the benefits and risks for patients, a panelist reported. Treatment plans should therefore be tailored to individual patients, taking into account a range of factors. The panelist highlighted that while combination therapies can improve progression-free survival, response rates, and duration of response, they also increase the likelihood of adverse effects. Consequently, treatment selection necessitates a careful evaluation of patient-specific factors. These factors include the presence of central nervous system (CNS) metastases, the patient’s performance status, their preferences regarding treatment aggressiveness, and real-world limitations. The panelist noted that patients in clinical practice often differ from those enrolled in clinical trials, presenting with conditions such as organ dysfunction, concomitant medications, and a history of previous treatments.

Newsflash | Powered by GeneOnline AI
Date: April 25, 2025

Related posts:

Momelotinib Data Shows Anemia Improvement and Tolerability in Myelofibrosis Patients in Real-World Use Popular diabetes medications, including GLP-1 drugs, may protect against Alzheimer’s disease Cefiderocol Study Finds Different Common Adverse Effects Than Prescribing Information FDA Appoints New Deputy Commissioner, Part of Three New Leadership Roles

Author

Mark Chiang